Pulmonary hypertension (PH) is a complex and often misdiagnosed condition that requires a comprehensive understanding for effective management. This article aims to provide an in-depth guide to PH, focusing on its pathophysiology, diagnosis, and treatment strategies.
PH is characterized by elevated pulmonary arterial pressure and pulmonary vascular resistance, leading to right ventricular failure. It is classified into five groups based on etiology: pulmonary arterial hypertension (PAH), PH due to left heart disease, PH due to lung diseases and/or hypoxia, chronic thromboembolic PH, and PH with unclear multifactorial mechanisms.
Diagnosis of PH is a multi-step process involving clinical assessment, echocardiography, and right heart catheterization. Echocardiography serves as an initial screening tool, while right heart catheterization confirms the diagnosis by directly measuring pulmonary pressures. Other diagnostic investigations include lung function tests, chest radiography, and computed tomography (CT) scan to identify underlying causes.
Treatment of PH is tailored according to its etiology and severity. General measures include lifestyle modifications, oxygen therapy, and anticoagulation. Specific treatment for PAH includes endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin analogs. In severe cases, lung transplantation may be considered.
Healthcare professionals play a crucial role in the early detection and management of PH. A high index of suspicion is required in patients presenting with unexplained dyspnea. Multidisciplinary approach involving cardiologists, pulmonologists, radiologists, and pathologists is often required for optimal patient care.
PH is a complex disease requiring a comprehensive understanding for effective management. Early diagnosis and appropriate treatment can significantly improve patient outcomes. Continuous education and collaboration among healthcare professionals are essential in achieving this goal.
1.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
2.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
3.
Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.
4.
Radiation therapy can promote amphiregulin, which increases growth of metastases
5.
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
1.
Learning from Uncommon Inherited Bleeding Disorder Presentations
2.
Essential Strategies in Hematology for Healthcare Excellence
3.
An Overview Of Leukemia Cutis: What It Is And How To Treat It
4.
All About Ferric Gluconate – The Best Source Of Iron For Anemia
5.
Lymphomatoid Papulosis: What You Need to Know
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV
4.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation